Hide Message

Updating the Resource Centre Digital Platform

The Business & Human Rights Resource Centre is at a critical point in its development. Our digital platform is home to a wealth of information on business and human rights, but hasn’t had a visual refresh for a number of years.

We will soon be updating the site to improve its usability and better serve the thousands of people that use our site to support their work.

Please take an advance peek at our new look, and let us know what you think!

Thank you,
Alex Guy, Digital Officer

Find Out More Hide Message

Ending the R&D Crisis in Public Health: Promoting pro-poor medical innovation

Author: Oxfam International, Published on: 1 November 2008

Insufficient resources are dedicated to developing the new vaccines, diagnostics, and medicines that can address health needs in developing countries…Pharmaceutical companies do not prioritise R&D to address diseases of the developing world, due to lower financial returns…the WTO TRIPS Agreement…failed to boost R&D in pharmaceuticals to satisfy the needs of developing countries, and it provides monopolies to pharmaceutical companies that result in unaffordable prices for medicine…Three main barriers hinder progress:…Insufficient financing…; lack of bold and creative thinking about incentive mechanisms…; absence of coordination concerning R&D…[refers to Abbott, Bristol-Myers Squibb, Eli Lilly, Genzyme, GlaxoSmithKline, Lupin, Ranbaxy, Roche, Wyeth]

Read the full post here

Related companies: Abbott Laboratories Bristol-Myers Squibb Eli Lilly Genzyme GlaxoSmithKline Lupin Ranbaxy Laboratories Roche Wyeth (part of Pfizer)